Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Expected To Confirm AZ Vaccine Link To Rare Blood Clot

Netherlands Latest To Suspend Use

Executive Summary

Growing evidence of an association between the vaccine and rare, sometimes fatal blood clots puts Europe’s vaccine program leaders in a difficult position.

You may also be interested in...



AZ Vaccine Safety: Germany Introduces Age Restrictions, But EMA Says Rare Blood Clot Link Still Unproven

The European Medicines Agency will reach its scientific conclusion next week, but countries are already moving to restrict use of the vaccine.

After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino On Possible ‘Class Effect’

Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.

After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino

Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel